The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumDigital Conferences - On Wednesday December 4th, 2024 PropThink hosted a live webinar with 3 incredible Key Opinion Leaders (“KOLs”) to discuss Duchenne Muscular Dystrophy (“DMD”) and learn … Continue Reading
Read nowInsights - The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns to that of checkpoint inhibitors … Continue Reading
Read nowInsights - One of the names we wrote about back in mid-December as a trade due to its ample cash position and negative enterprise value was Mural … Continue Reading
PremiumInsights - In a prior note, we covered the impact that GLP-1 drug class would have on related markets. On this note, we’ll focus on NASH (now … Continue Reading
Read nowInsights - Participants PropThink Dr. Michael Chancellor, KOL Jonathan Kaufman, Lipella CEO PropThink Good afternoon everyone, welcome to PropThink’s Digital Conference. My name is Deniel Mero, Editor … Continue Reading
Read nowInsights - Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately six months to approve devices … Continue Reading
PremiumInsights - Biotech has roared back and seen a strong start to the new year. Since November, in less than 3 months, the XBI is up 32%. … Continue Reading
Read now
